2009
Factor VII–Verteporfin for Targeted Photodynamic Therapy in a Rat Model of Choroidal Neovascularization
Lu F, Hu Z, Sinard J, Garen A, Adelman RA. Factor VII–Verteporfin for Targeted Photodynamic Therapy in a Rat Model of Choroidal Neovascularization. Investigative Ophthalmology & Visual Science 2009, 50: 3890-3896. PMID: 19357351, DOI: 10.1167/iovs.08-2833.Peer-Reviewed Original ResearchConceptsVisudyne photodynamic therapyChoroidal neovascularizationCNV lesionsTargeted photodynamic therapyDay 7Rat modelSafety of PDTPhotodynamic therapyOcular side effectsBrown Norway ratsFrequency of leakageFluorescein angiographyEfficacious doseHistopathologic evaluationLaser photocoagulationSide effectsFactor VIIDay 14LesionsNormal vasculatureRatsEndothelial cellsTherapyDoseNeovascularization
2008
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefe's Archive For Clinical And Experimental Ophthalmology 2008, 247: 171. PMID: 18781316, DOI: 10.1007/s00417-008-0936-y.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideBevacizumabChoroidal NeovascularizationDisease Models, AnimalDose-Response Relationship, DrugFluorescein AngiographyInjectionsLight CoagulationMacular DegenerationRanibizumabRatsRats, Inbred BNVascular Endothelial Growth Factor AVitreous BodyConceptsLeakage of CNVTreatment of CNVPegaptanib sodiumChoroidal neovascularizationIntravitreal injectionRat modelBackgroundVascular endothelial growth factorAnti-VEGF agentsEffect of bevacizumabAnti-VEGF medicationsBrown Norway ratsEndothelial growth factorNon-human primatesAngiography 1Histopathologic toxicityIntravitreal bevacizumabCNV leakageFluorescein angiographyLaser photocoagulationBevacizumabTherapeutic effectCNV lesionsRanibizumabDay 1Important stimulator